The application of Lapatinib in breast cancer and its mechanism of drug resistance
10.11904/j.issn.1002-3070.2015.04.020
- VernacularTitle:拉帕替尼在乳腺癌中的应用及其耐药机制研究现状
- Author:
Ge DU
;
Zefei JIANG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Receptor;
Epidermal growth factor;
Lapatinib
- From:
Practical Oncology Journal
2015;(4):376-379
- CountryChina
- Language:Chinese
-
Abstract:
With development of molecular biology,breast cancer has entered an era of molecular classifi-cation,thus making biomarker based personalized medicine is the trend of breast cancer treatment.HER2-posi-tive breast cancer of high invasiveness and bad prognosis accounts for 20%~30%.Targeting HER2,trastuzumab is the first humanized monoclonal antibody which can improve the prognosis of HER2-positive patients and it is recommended by guidelines and expert consensus at home and abroad for anti-HER2 therapy in any stage.How-ever,the cardiotoxicity,de novo resistance and acquired resistance of trastuzumab make the clinician to explore the second line anti-HER2 therapy.Lapatinib is the first FDA approved and HER1,HER2 double-targeting tyrosine kinase inhibitor which can be a better choice after failure with trastuzumab.This article reviews the appli-cation,some clinical and mechanism of drug resistance researches of Lapatinib.
